Fennec Pharmaceuticals Inc. (FENC)

Market Cap	243.04M
Revenue (ttm)	30.91M
Net Income (ttm)	-14.44M
Shares Out	27.62M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	27.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,313
Open	8.57
Previous Close	8.54
Day's Range	8.38 - 8.88
52-Week Range	3.96 - 8.88
Beta	0.40
Analysts	Strong Buy
Price Target	13.00 (+47.73%)
Earnings Date	Aug 12, 2025

About FENC

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2001
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: FENC
• Website: https://fennecpharma.com

Financial Performance

In 2024, Fennec Pharmaceuticals's revenue was $47.54 million, an increase of 123.69% compared to the previous year's $21.25 million. Losses were -$436,000, -97.28% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 47.73% from the latest price.

Price Target

$13.0

(47.73% upside)

Analyst Consensus: Strong Buy